Branched linker for protein drug conjugates

Patent metadata

Field	Value
Publication number	US-10294270-B2
Application number	US-201214001237-A
Country	US
Kind code	B2
Filing date	Feb 23, 2012
Priority date	Feb 25, 2011
Publication date	May 21, 2019
Grant date	May 21, 2019

Abstract

The present invention relates to method for connecting a protein and a drug to a protein drug conjugate, wherein the drug is linked to the protein through a specific branched linker, said branched linker comprises a peptide chain and is derived from o-hydroxy p-amino benzylic alcohol, wherein the peptide chain is connected to the phenyl ring via the p-amino group, the drug is connected to the phenyl ring via the benzylic alcohol moiety, and the protein is connected to the phenyl ring via the o-hydroxy group; further to a process for the preparation of said protein-drug-conjugates via various intermediates, to the pharmaceutical use of such protein drug conjugates, such as methods of controlling the growth of undesirable cells, to pharmaceutical compositions comprising such protein drug conjugates, and to intermediates of the preparation of the protein drug conjugates.

First claim

The invention claimed is:

1. A method (MI) for connecting a ligand LI with a drug DR, the method comprising
covalently connecting the ligand LI to the drug DR using a linker LIN,
wherein the connecting step forms a ligand-linker-drug conjugate, wherein
LI is selected from the group consisting of amino acids LI-AA, mono- or polyclonal antibodies LI-Ab, antibody fragments LI-AbFrag, proteins LI-Prot and peptides LI-Pep;
DR is a pharmaceutically active drug;
LIN comprises a connecting group CG2; and
CG2 is a connecting group of formula (CG2-1)

wherein
(***) denotes the connecting site which is used to connect LI;
(****) denotes the connecting site which is used to connect DR;
(******) denotes the connecting, site to which a linear peptide is connected, said peptide having, 2 to 8 amino acid residues.

2. The method (MI) according to claim 1 , wherein the ligand-linker-drug conjugate is in the form of a compound of formula (I),

wherein
T1 is —S—, —O— or —NH—;
T2 is —N(R4)-, —O— or —S—;
R4 H or C 1-4 alkyl;
T4 —O—;
n1 is 0 or 1;
n2 is 0 or 1;
n3 is 2, 3, 4, 5, 6, 7 or 8;
n4 is an integer from 1 to n3;
CG1 is a connecting group selected from the group consisting of a connecting group of formula (CG1-I) and spacer group of formula (CG1-II), a connecting group of formula (CG1-III) and a connecting group of formula (CG1-IV);

wherein
m30 and m32 are identical or different and independently from each other 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10;
(*) in the formulae of CG1 denotes the bond between T1 and CG1, the covalently connected LI forms in compound of formula (I) a ligand residue LIRes, which is covalently connected to CG1 via T1;

LI is a compound of formula (LIRes-T1-H);
LIRes-T1-H  (LIRes-H)

LIRes is selected from the group consisting of amino acid residue LIRes-AA, mono- or polyclonal antibody residue LIRes-Ab, antibody fragment residue LIRes-AbFrag, protein residue LIRes-Prot and peptide residue LIRes-Pep;

LI has a functional group selected from the group consisting of SH, OH or NH 2 , which forms in formula (I) the T1, the T1 is bonded to CG1 via the bond (*);
SG is a spacer group selected from the group consisting of a spacer group of formula (SG-II) and a spacer group of formula (SG-III);

wherein
m1 and m2 are identical or different and independently from each other 0 or 1;
m10, m11 and m12 are identical or different and independently from each other 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10;
with the proviso, that m2 and m10 are not simultaneously 0 and that m1 , m11 and m12 are not simultaneously 0;
SGPEG is a connecting group of formula (SGPEG-I);

wherein
 m20 is 1, 2, 3, 4, 5 or 6;

CG3 is selected from the group consisting of connecting group of formula (CG3-I) and connecting group of formula (CG3-II);

wherein
R5 and R6 are identical or different and independently from each other C 1-4 alkyl;

(******) in the formulae of CG2 denote the bond between to CG2 and AA n4 ;

the covalently connected DR forms in compound of formula (I) a drug residue DRRes, which is covalently connected to CG2 via T2;
DR is a compound of formula (DDRes-T2-H);
H-T2-DRRes  (DRRes-T2-H)

DRRes is a drug residue derived from DR;
DR has a functional group selected from the group consisting of —N(R4)H, —OH or —SH, which forms in formuls (I) the T2;
AA n4 is an amino acid residue and (AA n4 ) n3 is a linear peptide with n3 amino acid residues wherein n4 denotes the position of the amino acid residue in the peptide starting from CG2 with AA 1 being the first amino acid residue in the chain and being connected to CG2 via the bond (******), with the bond (******) being an amide bond of the carboxylic acid group of AA 1 with the amino group of CG2, and the AA n3 being the last amino acid residue in the chain, and with the individual amino acid residues being independently from each other identical or different, wherein the individual amino acid residures are connected to each other via a peptide bond;
(3) denotes the N-terminal amino group of said linear peptide, which is the amino group of AA n3 ;
R1 and R2 are identical or different and independently from each other selected from the group consisting of hydrogen, C 1-4 alkyl, C(O)—(CH 2 —O—) m5 -(GRPEG) m4 -R3 and PGN;
R3 C 1-4 alkyl;
m4 is 0 or 1;
m5 is 0 or 1;
PGN is a protecting group;
GRPEG is a connecting group of formula (GRPEG-I);

wherein
m21 is 1, 2, 3, 4, 5 or 6

wherein
if n1 being 1, the (**) in the formulae of CG1 and the (**) in the formula of SG denote the bond between CG1 and SG and the (***) in the formula of SG and the (***) in the formula of CG2 denote the bond between SG and CG2; and further wherein if n1 and CG1 is a connecting group of formula (CG1I), the nitrogen atom denoted with (**) in SG forms an endocyclic nitrogen atom thereby replacing the hydrogen atom of said nitrogen atom by an endocyclic bond;
if n1 is 0, the (**) in the formulae of CG1 and the (***) in the formula of CG2 denote the bond between CG1 and CG2; and further with the proviso that if n1 is 0 then CG1 is not a connecting group of formula (CG1-I);
if n2 is 1, the (****) in the formula of CG2 denotes the bond between CG2 and T4 and the (****) in the formula of CG3 denote the bonds between CG3 and T4; and further wherein n2 is 1, the (*****) in the formula of CG3 denotes the bond between CG3 and T2; and
if n2 being 0, the (****) in the formula of CG2 denotes the bond between CG2 and T2.

3. The method (MI) according to claim 2 , the method comprising reacting a compound of formula (II) with a compound of formula (LIRes-T1H);

wherein
CG1M is a connecting group selected from the group consisting of connecting group of formula (CG1M-I), connecting group of formula (CG1M-II), connecting group of formula (CG1M-III) and connecting group of formula (CG1M-IV);

wherein
X1 is Cl, Br or I.

4. A method (MII) for the preparation of compound of formula (II), with the compound of formula (II) as defined in claim 3 ,
wherein
if n2 is 1 and CG3 is a connecting group of formula (CG3-I), then method (MII) comprises a step (MIIa) and a step (MIIb);
if n2 is 1 and CG3 is a connecting group of formula (CG3-II), then method (MII) comprises the step (MIIa), a step (MIIc), a step (MIId) and a step (MIIe);
if n2 is 0 and CG1M is a connecting group of formula (CG1M-IV) then method (MII) comprises one step, a step (MII0-IV), or two steps, a step (MII0-I-IVa) and a step (MII0-1-IVb);
if n2 is 0 and CG1M is a connecting group of formula (CG1M-III) then

Assignees

• Ducry Laurent
• Stump Bernhard
• Wong Heilam
• She Jin
• Allway Gayle
• Lonza Ag
• Lonza Guangzhou Nansha Ltd

Inventors

• Ducry Laurent
• Stump Bernhard
• Wong Heilam
• She Jin
• Allway Gayle

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61K47/6845

  the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon · CPC title

• C07K5/06043 Primary

  Leu-amino acid · CPC title

• A61K47/6809

  Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin · CPC title

• A61K47/60 Primary

  the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol · CPC title